Fundraising FoxNilo Therapeutics
New York, US · Founded 2024 · 6 known investors
Find your way into Nilo Therapeutics
Sign up to see every warm intro you have to Nilo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nilo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases. Its approach is focused on restoring immune homeostasis in conditions with large unmet medical need.
Founders & leadership
Board
Investors · 6
How we know: DCVC (Data Collective)'s portfolio page · Not right? Tell us
How we know: The Column Group's portfolio page · funding news · biospace.com · the VCSheet dataset · Not right? Tell us
How we know: biospace.com · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$110.6M disclosed across 2 rounds · 2024–2025
- $101MSeries AOct 2025 · 5 sources
DCVC Bio (lead), Lux Capital (lead), The Column Group (lead), Alexandria Venture Investments, Gates Foundation
Source ↗
▶$9.6MraisedAug 2024 · 3 investors · BiotechnologyRule 506(b)
- Tim KutzkeyExecutive Officer, Director, Promoter
- Jeff GoaterExecutive Officer, Director
- Offering amount
- $101M
- Amount sold
- $9.6M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Nilo Therapeutics do?
- Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases. Its approach is focused on restoring immune homeostasis in conditions with large unmet medical need.
- Who are Nilo Therapeutics's investors?
- Nilo Therapeutics's investors include DCVC (Data Collective), The Column Group, Alexandria, DCVC Bio, Lux Capital.
- How much funding has Nilo Therapeutics raised?
- Nilo Therapeutics has disclosed $110.6M raised across 2 rounds.
- Where is Nilo Therapeutics headquartered?
- Nilo Therapeutics is headquartered in New York, US.